Combination treatment for allergic rhinitis: optimum solution
DOI: 10.32364/2587-6821-2020-4-1-62-65
O.M. Kurbacheva, I.I. Isakova
NRC Institute of Immunology, Moscow, Russian Federation
The major goals of the treatment of allergic rhinitis (AR) are to establish and maintain disease control, to relief symptoms, to reduce the risk of complications, and to improve the quality of life. AR treatment requires complex approach. Disease course, symptom severity, individual social and psychological patient’s characteristics, and comorbidities should be considered. Patient education programs, elimination measures, allergen-specific immunotherapy, and pharmacotherapy are important as well.
Since AR is mediated by allergic inflammation which involves numerous cells and mediators, the key role of histamine and cysteinyl leukotrienes in the development of AR clinical symptoms is well established. As a result, antihistamine drugs and leukotriene receptor antagonists are widely used to treat AR. Levocetirizine is a second-generation H1 blocker while montelukast is an antileukotriene. Combination of these drugs is the first-line treatment strategy for AR.
Keywords: allergic rhinitis, antihistamine therapy, H1 blockers, antileukotriene receptor antagonists, levocetirizine, montelukast, Montlesir.
For citation: Kurbacheva O.M., Isakova I.I. Combination treatment for allergic rhinitis: optimum solution. Russian Medical Review. 2020;4(1):62–65. DOI: 10.32364/2587-6821-2020-4-1-62-65.
About the authors:
Oksana M. Kurbacheva — MD, PhD, Professor, Head of the Department of Asthma, ORCID ID 0000-0003-3250-0694;
Irina I. Isakova — MD, PhD, allergist and immunologist of the Department of Asthma, ORCID iD 0000-0003-4973-8930.
NRC Institute of Immunology. 24, Kashirskoe road, Moscow, 115478, Russian Federation.
Contact information: Oksana M. Kurbacheva, e-mail: kurbacheva@gmail.com. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 18.02.2020.
2. Brozek J.L., Bousquest J., Agache I. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines — 2016 Reversion. J Allergy Clin Immunol. 2017;140(4):950–958. DOI: 10.2016/j.jaci.2017.03.050.
3. Sami A.M., Ahmed N., Ahmed S. The effect of nover combination therapy with azelastine hydrochloride and fluticasone propionate in allergic rhinitis. Otolaryngol. (Sunnyvale.) 2016;6:4. DOI: 10.4172/2161-119X.1000261.
4. Gillard M., van Der Perren C., Moguilevsky N. et al. Binding characteristics of cetirizine and levocetirizine to human H1-histamine receptors: contribution of Lys (191) and Thr (194). Mol Pharmacol. 2002:(61);391–399. DOI: 10.1124/mol.61.2.391.
5. Molimard M., Diquet B., Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 2004:(18);399–411. DOI: 10.1111/j.1472-8206.2004.00254.x.
6. Bachert C., Bousquet J., Canonica G.W. et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004:(114);838–844. DOI: 10.1016/j.jaci.2004.05.070.
7. Инструкция по медицинскому применению лекарственного препарата Монтлезир. (Электронный ресурс). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1397f4d9–58db-4ce7–8fb2-f7ee4bbf02dcandt=. Дата обращения: 03.02.2020. [Instructions for the medical use of the drug Montlesir. (Electronic resource). URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1397f4d9–58db-4ce7–8fb2-f7ee4bbf02dcandt=. Access date: 03.02.2020 (in Russ.)].
8. Borderias L., Mincewicz G., Paggiaro P.L. et al. Asthma control in patients with asthma and allergic rhinitis receiving add on montelukast therapy for 12 month: a retrospective observational study. Curr Med Res Opin. 2007;(23):721–730. DOI: 10.1185/030079906X167606.
9. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization; 2003.
10. Baççioğlu A., Yorgancioğlu A., Cingi C., Çuhadaroğlu C. Role of leukotriene antagonists and antihistamines in treatment of allergic rhinitis and asthma comorbidity. J Med Updates. 2013;3(1):34–39. DOI:10.2399/jmu.2013001008.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
